Senseonics Target of Unusually High Options Trading (NYSE:SENS)

Senseonics Holdings, Inc. (NYSE:SENS) saw unusually large options trading on Monday. Investors acquired 4,425 call options on the stock. This is an increase of 63% compared to the typical daily volume of 2,719 call options.

Senseonics Stock Down 19.3 %

SENS stock opened at $0.70 on Wednesday. Senseonics has a 52 week low of $0.25 and a 52 week high of $1.40. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. The firm has a 50-day simple moving average of $0.85 and a 200-day simple moving average of $0.53. The stock has a market capitalization of $417.92 million, a P/E ratio of -5.40 and a beta of 0.69.

Senseonics (NYSE:SENS) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.09). Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. During the same period in the previous year, the firm earned ($0.07) EPS. Equities analysts forecast that Senseonics will post -0.14 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Timothy T. Goodnow acquired 315,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was bought at an average price of $0.31 per share, with a total value of $97,650.00. Following the completion of the acquisition, the chief executive officer now owns 11,310,355 shares of the company’s stock, valued at approximately $3,506,210.05. This represents a 2.86 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Frederick T. Sullivan bought 124,933 shares of the stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the completion of the purchase, the chief financial officer now owns 2,478,844 shares in the company, valued at approximately $941,960.72. This represents a 5.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Two Sigma Investments LP acquired a new stake in Senseonics during the fourth quarter worth about $36,000. Millennium Management LLC lifted its holdings in Senseonics by 299.0% in the fourth quarter. Millennium Management LLC now owns 1,088,029 shares of the company’s stock valued at $569,000 after acquiring an additional 815,332 shares during the last quarter. Jane Street Group LLC grew its position in Senseonics by 6,694.1% in the fourth quarter. Jane Street Group LLC now owns 6,118,786 shares of the company’s stock worth $3,203,000 after acquiring an additional 6,028,726 shares during the period. First Light Asset Management LLC purchased a new stake in Senseonics in the fourth quarter valued at $3,366,000. Finally, Northern Trust Corp grew its holdings in shares of Senseonics by 11.2% during the 4th quarter. Northern Trust Corp now owns 1,194,960 shares of the company’s stock worth $625,000 after purchasing an additional 120,441 shares during the period. Hedge funds and other institutional investors own 12.36% of the company’s stock.

Wall Street Analyst Weigh In

SENS has been the topic of a number of recent analyst reports. StockNews.com assumed coverage on Senseonics in a research report on Thursday, December 26th. They set a “sell” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $2.00 target price on shares of Senseonics in a research report on Friday, November 15th.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.